Related coverage linked through entity extraction aliases.
Mar 18, 2026
Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.
Mar 16, 2026
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Mar 11, 2026
Researchers at the Regina Elena National Cancer Institute in Rome discovered how the hMENA protein enables non-small cell lung cancer to resist immunotherapy by regulating cancer-associated fibroblasts that create a protective tumor microenvironment.
Mar 11, 2026
Recent studies demonstrate PD-1 antibody combinations improve survival in natural killer/T-cell lymphoma and show activity in previously treated advanced non-small cell lung cancer, with manageable safety profiles across treatment settings.
Mar 11, 2026
AstraZeneca terminated its Phase I/IIa trial of AZD0022 for KRASG12D-mutant cancers, withdrew a planned saruparib ovarian cancer platform study, and completed a real-world non-small cell lung cancer treatment review.
Mar 10, 2026
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
Mar 09, 2026
A study published in Nature Microbiology demonstrates that a defined consortium of 15 gut bacterial species derived from immunotherapy responders significantly enhances anti-PD-1 treatment efficacy in mouse models of non-small-cell lung cancer.
Mar 08, 2026
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Mar 07, 2026
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
Mar 05, 2026
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Mar 03, 2026
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Mar 02, 2026
Merck is diversifying its oncology pipeline beyond Keytruda as the blockbuster approaches patent cliffs, focusing on immune modulating therapies, antibody-drug conjugates, and tumor intrinsic treatments through strategic acquisitions and partnerships.
Feb 26, 2026
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Feb 21, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
Feb 18, 2026
OncoHost announced publication of a study in JPBA introducing a computational framework that harmonizes serum and plasma proteomic datasets, enabling researchers to combine previously incompatible specimen types for biomarker research.
Feb 26, 2026
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
Feb 20, 2026
Researchers develop a nanoplatform that co-induces cuproptosis and disulfidptosis to upregulate PD-L1 expression and sensitize tumors to immune checkpoint blockade therapy, addressing resistance in PD-L1-low malignancies.
Feb 20, 2026
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
Feb 18, 2026
Flatiron Health announced its first Panoramic datasets for prostate cancer patients in the UK and Germany, encompassing records of nearly 400,000 patients across three countries. The datasets leverage AI and large language models to provide unified real-world evidence for cancer research.
